Oral administration of valganciclovir reduces clinical signs, virus shedding and cell-associated viremia in ponies experimentally infected with the equid herpesvirus-1 c2254 variant

HIGHLIGHTS

• who: Cu00f4me J. Thieulent and colleagues from the 450, Normandie University, UNICAEN, Saint-Contest, France have published the Article: Oral Administration of Valganciclovir Reduces Clinical Signs, Virus Shedding and Cell-Associated Viremia in Ponies Experimentally Infected with the Equid Herpesvirus-1 C2254 Variant, in the Journal: Pathogens 2022, 539 of 24/03/2022
• what: The study aimed to measure the therapeutic efficacy of 2 weeks of VGCV treatment orally administrated immediately after experimental EHV-1 infection (FR- 56628; EHV-1 ORF30 C2254 variant). In the present study, all infected ponies developed respiratory signs two days . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.